Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV versus nebulized dexmedetomidine for preoperative sedation in pediatric adenotonsillectomy
PACTR202511627656950Phase 1Unknown
- Sponsor
- Alaa Eldin Abdel Sami Aiad
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexmedetomidine in Adenotonsillar hypertrophy (ATH) (2 arms), sponsored by Alaa Eldin Abdel Sami Aiad. Primary endpoint: Cumulative dexmedetomidine dose required to reach target sedation. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Adenotonsillar hypertrophy (ATH)
Beyond the preview
Go deeper on PACTR202511627656950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511627656950.